Your Good Partner in Biology Research

  1. Home
  2. 抗体
  3. 多克隆抗体
  4. BRMS1 Antibody

BRMS1 Antibody

  • 货号：
    CSB-PA004983
  • 规格：
    ￥880
  • 图片：
    • Western Blot analysis of HT29 K562 BT474 cells using BRMS-1 Polyclonal Antibody
  • 其他：

产品详情

  • Uniprot No.：
    Q9HCU9
  • 基因名：
    BRMS1
  • 别名：
    AV003220 antibody; AW554636 antibody; Breast cancer metastasis suppressor 1 antibody; Breast cancer metastasis-suppressor 1 antibody; BRMS1 antibody; BRMS1_HUMAN antibody; DKFZp564A063 antibody; MGC95128 antibody
  • 宿主：
    Rabbit
  • 反应种属：
    Human,Mouse,Rat
  • 免疫原：
    Synthesized peptide derived from the C-terminal region of Human BRMS-1.
  • 免疫原种属：
    Homo sapiens (Human)
  • 标记方式：
    Non-conjugated
  • 抗体亚型：
    IgG
  • 纯化方式：
    The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
  • 浓度：
    It differs from different batches. Please contact us to confirm it.
  • 保存缓冲液：
    Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
  • 产品提供形式：
    Liquid
  • 应用范围：
    WB, ELISA
  • 推荐稀释比：
    Application Recommended Dilution
    WB 1:500-1:2000
    ELISA 1:20000
  • Protocols：
  • 储存条件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 货期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

产品评价

靶点详情

  • 功能：
    Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.
  • 基因功能参考文献：
    1. BRMS1FANCI interaction is necessary for the regulatory role of BRMS1 in the FA pathway. PMID: 30365131
    2. overexpression of miR-3200-5p significantly decreased BRMS1 levels and promoted OS cell invasion and migration, while depletion of miR-3200-5p significantly increased BRMS1 levels and inhibited OS cell invasion and migration. Study revealed that miR-3200-5p may be a critical regulator of OS cell invasiveness. PMID: 29890825
    3. Low BRMS1 expression is associated with Hepatocellular carcinoma. PMID: 29295726
    4. Low BRMS1 expression is associated with high metastatic capacity of breast cancer. PMID: 29970691
    5. High BRMS1 Expression is associated with Metastases and recurrence in Lung Adenocarcinoma. PMID: 29097253
    6. The results showed that reduction in the breast cancer metastasis suppressor 1 [BRMS1] expression level was linked directly to clinico-pathological features of breast cancer significantly. The loss of expression or reduced levels of BRMS1 is potentially a strong indicator of the metastatic capacity of breast cancer with poor prognosis. PMID: 28533425
    7. The RAS-related nuclear protein ((P) ran), breast cancer metastasis suppressor 1 ((P) brms1) and minichromosome maintenance complex component 5 ((P) mcm5) promoters have the specificity and strength needed for cancer-specific expression-targeted gene therapy. PMID: 27140445
    8. we identify a therapeutically exploitable posttranslational mechanism by which CK2alpha-mediated degradation of BRMS1 promotes metastases in lung cancer PMID: 26980766
    9. our study characterized DAPK1 as a novel transcriptional target of BRMS1. Transcriptional activation of DAPK1 might be another important mechanism accounting for the metastasis suppressive activity of BRMS1. PMID: 28339067
    10. BRMS1 promoter methylation and aberrant protein expression seem to be related to high-risk types of human papilloma virus-induced carcinogenesis in uterine cervix. PMID: 28381193
    11. miR-346 promotes migration and invasion of nasopharyngeal carcinoma cells via targeting BRMS1. PMID: 27501413
    12. A novel link has been discussed between CDK2 expression and cell migration by characterizing the CDK2-mediated phosphorylation of BRMS1. PMID: 26730572
    13. Phosphorylation of BRMS1 by CDK2 regulates the migration of tumor cells. PMID: 26771717
    14. Data show that Cullin3 exerts its function through promoting breast-cancer metastasis suppressor 1 (BRMS1) protein degradation, which was associated with epithelial-mesenchymal transition (EMT), migration and invasion. PMID: 26544623
    15. The studies reviewed here with respect to BRMS1 structure, cellular effects, intracellular signaling, and clinical value consolidate the importance of BRMS1 in the development of metastasis. PMID: 26328523
    16. Aberrant methylation of BRMS1 frequently occurs in the down-regulation of BRMS1 in triple negative breast cancer and that it may play a role in the metastasis of breast cancer. PMID: 26617826
    17. the present study demonstrates a mechanical cascade of BRMS1 suppressing cancer cell invasion through downregulating HIF-1alpha transcript and consequently reducing Snail and TWIST1 expression. PMID: 26520789
    18. MRTF-A and STAT3 synergistically recruited DNMT1 to hypermethylate the promoter of BRMS1 and affect the expression of BRMS1.MRTF-A and STAT3 promote breast cancer cell migration via hypermethylating BRSM1. PMID: 25854163
    19. BRMS1 expression in human breast cancer is negatively correlated with JARID1C expression. Our results, for the first time, portray a pivotal role of JARID1C in regulating metastatic behaviors of breast cancer cells PMID: 26182878
    20. high expression of BRSM1 in rectal cancer plays an essential role in tumor progression PMID: 24748145
    21. loss of BRMS1 promotes malignant phenotypes that are dependent on NF-kappaB-dependent regulation of Twist1 PMID: 25368381
    22. BRMS1 is a key regulator required to maintain a cellular morphology and cytoskeletal architecture consistent with an epithelial phenotype. PMID: 24763730
    23. BRMS1 overexpression inhibited glioma cell invasion. PMID: 24879377
    24. BRMS1-expressing cells remained rounded. PMID: 24000122
    25. Silencing of BRMS 1 significantly induced the expression of NF-kappaB subunit, p65, uPA, and OPN proteins PMID: 24984534
    26. Methylation of BRMS1 promoter in cfDNA isolated from plasma of NSCLC patients provides important prognostic information and merits to be further evaluated as a circulating tumour biomarker. PMID: 24642624
    27. Data define BRMS1 promoter methylation in primary breast tumors and associated circulating tumor cells. PMID: 23744981
    28. Low levels of BRMS1 were observed in patients with high-grade tumors, in patients with distant metastasis in breast cancer. PMID: 24596389
    29. BRMS1 SNP rs1052566 heterozygous individuals were more likely to have node-positive breast tumors. PMID: 23771732
    30. Report BRMS1 transcript variant which regulates heptocellular carcinoma apoptosis and growth. PMID: 23643861
    31. s observed that residues 85 to 98 might be important in defining the oligomerization state of the BRMS1 N-terminal coiled coil. PMID: 23500495
    32. The C-terminal putative nuclear localization sequence (NSL2) of BRMS1 is necessary for metastasis suppression. PMID: 23390556
    33. Data suggest that low expression of the metastasis suppressor BRMS1 may be an independent prognostic factor for poor prognosis in nasopharyngeal carcinoma (NPC) patients. PMID: 22931099
    34. The expression of BRMS1 protein in supraglottic cancer is significantly decreased. BRMS1 gene promotor methylation is related with down-expression of BRMS1 protein. PMID: 23167184
    35. Data indicate that mutation of E3 ligase motif not only abolishes BRMS1-induced p300 polyubiquitination and degradation, but importantly, dramatically reduces the metastasis suppressor function of BRMS1. PMID: 23269275
    36. BRMS1 sensitizes HCC cells to apoptosis through suppressing OPN expression PMID: 22927944
    37. The loss of BRMS1 expression may be involved in the development and progression of nasal and paranasal sinus carcinomas. PMID: 22239051
    38. Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression. PMID: 22200669
    39. high level of expression and lack of promoter methylation are associated with better overall survival in non-small cell lung cancer patients PMID: 21726917
    40. These results suggest that the novel regulatory mechanism of BRMS1 by Cul3-SPOP complex is important for breast cancer progression. PMID: 22085717
    41. SATB1 and BRMS1 might play an important role in the development and lymph node metastasis of ovarian cancer. PMID: 21355308
    42. possible link between BRMS1 expression and apoptosis in human breast cancer through a relationship with the expression of genes belonging to the X-chromosome RBM family. PMID: 21737612
    43. the enigmatic complexities of BRMS1-mediated metastasis suppression PMID: 21827753
    44. The expression of BRMS1 protein in supraglottic cancer is significantly decreased. Expression has a close relationship with pathologic differentiation and clinical stage and cervical lymph node metastasis. PMID: 19621595
    45. Expression of BRMS1 mRNA in supraglottic cancer is lower than that in adjacent normal mucosa. PMID: 18533556
    46. BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. PMID: 20935672
    47. Study observed that SNX6 increases BRMS1-dependent transcriptional repression. Moreover, over-expression of SNX6 was capable of diminishing trans-activation in a dose-dependent manner. PMID: 20830743
    48. Patients with high levels of expression of BRMS1 mRNA have a better prognosis than those with low expression. PMID: 17085653
    49. ING4 is induced by BRMS1 and that it inhibits melanoma angiogenesis by suppressing NF-kappaB activity and IL-6 expression. PMID: 21056991
    50. BRMS1 expression in breast cancer cells induced reorganization of F-actin and caused alteration in cytoarchitectures (cell topography and ultrastructure). PMID: 20083343

    显示更多

    收起更多

  • 亚细胞定位：
    Nucleus. Cytoplasm. Note=Predominantly nuclear.
  • 蛋白家族：
    BRMS1 family
  • 组织特异性：
    Expression levels are higher in term placentas than in early placentas. Low levels of expression observed in normal pregnancies and in molar pregnancies.
  • 数据库链接：

    HGNC: 17262

    OMIM: 606259

    KEGG: hsa:25855

    STRING: 9606.ENSP00000396052

    UniGene: Hs.100426